Exicure, Inc., a biotechnology company specializing in gene regulatory and immunotherapeutic drugs, announced the scheduling of its combined 2024 and 2023 Annual Meeting of Stockholders to be held virtually on June 28, 2024. The meeting will address the election of Class III and Class I directors, ratification of the company's independent auditor, advisory approval of executive compensation, and the frequency of such compensation reviews. The meeting will also cover any additional business that may arise. The record date for determining stockholder eligibility to vote at the meeting is set for May 15, 2024. Stockholders will be able to attend the meeting online, submit questions, and vote their shares electronically. The company did not hold an Annual Meeting in 2023, making this a combined meeting for both years. Proxy materials, including the Proxy Statement and the 2023 Annual Report, are available online for stockholders.

Exicure, Inc., a biotechnology company specializing in gene regulatory and immunotherapeutic drugs, announced the scheduling of its combined 2024 and 2023 Annual Meeting of Stockholders to be held virtually on June 28, 2024. The meeting will address the election of Class III and Class I directors, ratification of the company's independent auditor, advisory approval of executive compensation, and the frequency of such compensation reviews. The meeting will also cover any additional business that may arise. The record date for determining stockholder eligibility to vote at the meeting is set for May 15, 2024. Stockholders will be able to attend the meeting online, submit questions, and vote their shares electronically. The company did not hold an Annual Meeting in 2023, making this a combined meeting for both years. Proxy materials, including the Proxy Statement and the 2023 Annual Report, are available online for stockholders.